• Purification Rate: 99.8% (0.22μm membrane filtration)
• Endotoxin Levels: <0.04 EU/
• Moisture Content: <3.0%
• Potency Variance: 100U ±10% per
• Excipients: 0.5mg Human Serum Albumin (HSA), 0.9mg NaCl

• Efficacy Rate: 89.4% improvement in moderate-to-severe glabellar lines (Week 4 analysis).
• Onset: Initial paresis at 48-72 hours.
• Peak Effect: Day 14 post-administration.
• Duration: 16-24 weeks baseline, dose-dependent.
• Diffusion: Controlled, minimal systemic spread.

Inject 2.5ml sterile, unpreserved 0.9% NaCl directly into the yielding a 4U/0.1ml concentration. Administer via 30G-32G. Unopened validate 36-month stability at 2-8°C or -5°C. Post-reconstitution, strictly maintain at 2-8°C and utilize within 24 hours to prevent peptide degradation.

Classified as a prescription biologic. Procurement and administration restricted exclusively to licensed medical personnel. Contraindicated for patients with known hypersensitivity, myasthenia gravis, Eaton-Lambert syndrome, or active injection site infections.